Chronic alcohol consumption is associated with the development of alcoholic liver disease (ALD), a major cause of morbidity and mortality in the U.S. including our Veteran population. Prominent features of ALD include ethanol-mediated cellular alterations, steatosis and hepatic inflammation; however, a comprehensive understanding of the mechanisms involved remains incomplete. It has previously been shown that hepatocellular protein trafficking pathways were found to be highly susceptible to the detrimental effects of alcohol. In particular, our laboratory identified multiple ethanol-induced alterations in the process of receptor- mediated endocytosis (RME) and more specifically, we discovered that ethanol treatment resulted in marked impairments in the function of the hepatocyte-specific asialoglycoprotein (ASGP) receptor. However, translating the observed alterations in ASGP receptor function to the incidence and/or severity of ALD remains uncharacterized. Recently it has been suggested that the recognition and subsequent regulation of immune cells could be a potential physiological role of the ASGP receptor. In preliminary studies for this proposal, we have demonstrated that the ASGP receptor specifically binds to lymphocytes and that the absence of the hepatic receptor results in the accumulation of intrahepatic T cells and enhanced liver injury. Therefore, we propose that the ASGP receptor has a role in the regulation of immune cells in the healthy liver and that ethanol-induced impairments in ASGP receptor function can result in increased liver injury caused by T cell- mediated events. The overall working hypothesis of this study is that ASGP receptors establish connections between hepatocytes and activated T lymphocytes (immune cells that are known to accumulate following liver injury) which facilitate the beneficial removal of potentially damaging T cells. Furthermore, as a consequence of ethanol-mediated alterations to the ASGP receptor, altered clearance of T cells occurs leading to abnormal lymphocyte accumulation, events that could contribute the development of hepatitis and the progression of ALD. We will address these hypotheses with the following specific aims: In initial studies, the recognition and binding of T lymphocytes to the hepatocyte ASGP receptor will be characterized in vitro. Next, lymphocyte clearance mechanisms (phagocytosis and/or T cell death mechanisms) triggered as a result of ASGP receptor- mediated hepatocyte-lymphocyte interactions will be analyzed. And finally, in vivo studies are proposed to demonstrate the importance of altered or absent functional ASGP receptors in the development of immune cell related liver injury using models of ethanol administration along with an ASGP receptor knockout mouse treated with inducers T cell-mediated hepatitis. Information gained from this research can significantly impact our understanding of how hepatocyte-lymphocyte interactions maintain proper T cell homeostasis in the liver and how impairments in such interactions can lead to enhancements in liver disease. Overall, this work aims to establish and characterize the role of the hepatic ASGP receptor in immune regulation and whether the alterations of this proce

Public Health Relevance

Current clinical issues in the VA Health Care Network include the treatment and intervention of liver disease that is associated with alcohol consumption. This proposal has the potential to impact those issues by investigating mechanisms that contribute to the development of alcohol-induced liver disease. Particularly, we aim to characterize liver cell defects and associated consequences that are induced by ethanol. We hypothesize that hepatocyte-lymphocyte interactions are impaired and that this event is related to the promotion of T cell-mediated liver damage. Overall, this proposed VA Merit aims to define key biochemical mechanisms associated with alcoholic hepatitis, a serious pre-cirrhotic form of alcoholic liver disease. Ultimately, our goal is to identify potential cellular targets for therapeutic intervention and treatment that will supplement veteran alcohol substance abuse programs.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX001041-04
Application #
8762408
Study Section
Gastroenterology (GAST)
Project Start
2011-10-01
Project End
2015-09-30
Budget Start
2014-10-01
Budget End
2015-09-30
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Omaha VA Medical Center
Department
Type
DUNS #
844360367
City
Omaha
State
NE
Country
United States
Zip Code
68105